TheEdgeResearch
Home / Stocks / LNSR

LENSAR Inc (LNSR)

NASDAQ Healthcare Medical - Devices
$4.46 ▼ -3.88%
Market Cap
$54.8M
Sector
Healthcare
Industry
Medical - Devices
Beta
1.03
52-Wk Range
4.3-12.94
CEO
Nicholas T. Curtis
Country
US
Currency
USD

LENSAR Inc operates in the Medical - Devices industry of the Healthcare sector, headquartered in Orlando, FL, US. The stock last traded at $4.46, down 3.88% on the session, giving a market capitalisation of $54.8M. On trailing twelve-month figures it carries a trailing P/E of 3.72, a net margin of 56.1%. Its beta of 1.03 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
3.72
Price / Sales
0.91
Price / Book
5.00
EV / EBITDA
1.26
Gross margin
52.0%
Operating margin
-3.3%
Net margin
56.1%
Return on equity
—
Debt / equity
0.20
Current ratio
2.25
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
150
IPO date
2020-10-02
Headquarters
Orlando, FL, US
About LENSAR Inc

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Comparable companies

LENSAR Inc is most often compared with the following Healthcare names:

ANIKARAYAVRCRBPCRDFMXCTOWLTPROFRPIDTLSI
More research on LNSR
LNSR technical analysis LNSR TheEdge Score Compare against peers
Open full interactive analysis & DCF →